Therefore, it is strongly recommended that patients diagnosed with adenocarcinoma and exhibiting HER2 overexpression be treated with trastuzumab in the initial CTH regimen, along with a fluoropyrimidine and a platinum agent (preferably oxaliplatin due to its lower toxicity compared to cisplatin). Here, ERBB2 is linked to adenocarcinoma.